WEAN: Utility of a Weaning Protocol in ICU

Sponsor
ELENA PELI,MD (Other)
Overall Status
Completed
CT.gov ID
NCT01877850
Collaborator
(none)
60
1
12
5

Study Details

Study Description

Brief Summary

The purpose of this study is to evaluate the difference of the duration of weaning process from the ventilator between protocol-driven weaned patients and clinical judgment driven weaned patients.

Condition or Disease Intervention/Treatment Phase
  • Procedure: weaning protocol

Detailed Description

All patients with prolonged weaning and who required tracheostomy are enrolled in the study. These patients are randomized as "Case or Control" by a computer program.

Patients can start the weaning process when the acute phase of the respiratory failure has been resolved and pressure support ventilation was setted.

For all this patients are calculated modified-BWAP(BWAP-M) and TOBIN indexes. The "Case" patients started the weaning protocol process only if BWAP-M value is more than 15 or BWAP-M 10-15 with Tobin index < 100.

If not, the BWAP-M and Tobin will be calculated every day. The Control patients will start weaning by clinical judgement even if the BWAP-M value is less than 10.

For all patients are calculated: the duration of weaning process, the ICU length of stay and the duration of the mechanical ventilation.

Study Design

Study Type:
Observational
Actual Enrollment :
60 participants
Observational Model:
Case-Control
Time Perspective:
Prospective
Official Title:
Non Pharmacological Randomized Clinical Trial Designed to Evaluate the Difference of the Duration of Weaning Process From the Ventilator Between Protocol-driven Weaned Patients and Clinical-driven Weaned Patients.
Study Start Date :
May 1, 2013
Actual Primary Completion Date :
May 1, 2014
Actual Study Completion Date :
May 1, 2014

Arms and Interventions

Arm Intervention/Treatment
case

patients with BPAW-M more than 15 or between 10 and 15, but with Tobin <100 will be weaned with the weaning protocol by nurses

Procedure: weaning protocol
Reduction of pressure support ventilation (PSV) by 2cmH2O at a time to a maximum of 4cmH2O per day. When a patient was able to tolerate PSV less than 8 cmH2O for at least 120 minutes, the nurses started to reduce End Expiratory Positive Pressure (PEEP) by 2cmH2O at a time to a maximum of 4cmH2O per day. When a patient was able to tolerate PSV less than 8 cmH2O with PEEP less than 6 cmH2O, the nurses started SBT trial: Continuos Positive Pressure Airways of 6cmH2O for at least 120 minutes and following discontinuation from ventilator.

control

patients with any BWAP-M will be weaned by clinical judgment of physicians

Outcome Measures

Primary Outcome Measures

  1. duration of weaning [within the first 15 days (plus or minus 5 days) after start of weaning]

Secondary Outcome Measures

  1. duration of mechanical ventilation [within the first 12 days (plus or minus 10 days) after start of mechanical ventilation]

Other Outcome Measures

  1. ICU length of stay [within the first 26 days (plus or minus 22 days) after ICU recovery]

  2. success of weaning [spontaneous breathing for 48 hours]

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. all patients that are clinically identified as prolonged to wean (failed 3 spontaneous breathing trials or 7 days or more of mechanical ventilation after the initial unsuccessful trial) and tracheostomized in ICU

  2. improvement or resolution of the underlying causes of acute respiratory failure ratio between pressure partial artery of oxygen and fraction inspired oxygen (PaO2/FiO2)

200 with fraction inspired oxygen (FiO2)< 0,45.

  1. pressure supported ventilation at the time of enrollment.
Exclusion Criteria:
  1. patients assessed as easy weaning and not tracheostomized;

  2. patients already tracheostomized on admission to ICU.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Institute of Anesthesiology and Intensive Care of the University of Brescia, Spedali Civili, Italy, Brescia Italy 25128

Sponsors and Collaborators

  • ELENA PELI,MD

Investigators

  • Principal Investigator: Elena Peli,

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
ELENA PELI,MD, dirigente medico, Università degli Studi di Brescia
ClinicalTrials.gov Identifier:
NCT01877850
Other Study ID Numbers:
  • NPn1351
First Posted:
Jun 14, 2013
Last Update Posted:
Apr 23, 2015
Last Verified:
Apr 1, 2015

Study Results

No Results Posted as of Apr 23, 2015